Ingrid Hedenfalk

6.0k total citations · 1 hit paper
78 papers, 2.4k citations indexed

About

Ingrid Hedenfalk is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Ingrid Hedenfalk has authored 78 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 31 papers in Molecular Biology and 30 papers in Cancer Research. Recurrent topics in Ingrid Hedenfalk's work include BRCA gene mutations in cancer (17 papers), Ovarian cancer diagnosis and treatment (13 papers) and Cancer Genomics and Diagnostics (12 papers). Ingrid Hedenfalk is often cited by papers focused on BRCA gene mutations in cancer (17 papers), Ovarian cancer diagnosis and treatment (13 papers) and Cancer Genomics and Diagnostics (12 papers). Ingrid Hedenfalk collaborates with scholars based in Sweden, United States and Denmark. Ingrid Hedenfalk's co-authors include Niklas Loman, Siker Kimbung, Ida Johansson, Markus Ringnér, Thomas Hatschek, Mårten Fernö, Håkan Olsson, Pär‐Ola Bendahl, Jonas Bergh and Carina Strand and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Nature Genetics.

In The Last Decade

Ingrid Hedenfalk

77 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression

2017 408 citations Asís Palazón, Petros A. Tyrakis et al. Cancer Cell profile →

Peers

Ingrid Hedenfalk

ONCOL

GENET

IMMUN

Petra van der Groep Netherlands

Marcello Maugeri‐Saccà Italy

Steven McKinney Canada

David A. Quigley United States

Paola Capodieci United States

Beatriz Martı́nez-Delgado Spain

Anita Mangia Italy

Francesco Schittulli Italy

Thomas Bogenrieder Germany

Paul van Diest Netherlands

Petra van der Groep Netherlands

Ingrid Hedenfalk

1.9k ×1.8

1.7k ×2.0

1.2k ×1.5

ONCOL

549 ×1.0

GENET

240 ×0.6

IMMUN

Citations per year, relative to Ingrid Hedenfalk Ingrid Hedenfalk (= 1×) peers Petra van der Groep

Countries citing papers authored by Ingrid Hedenfalk

Since Specialization

Citations

This map shows the geographic impact of Ingrid Hedenfalk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid Hedenfalk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid Hedenfalk more than expected).

Fields of papers citing papers by Ingrid Hedenfalk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid Hedenfalk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid Hedenfalk. The network helps show where Ingrid Hedenfalk may publish in the future.

Co-authorship network of co-authors of Ingrid Hedenfalk

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid Hedenfalk. A scholar is included among the top collaborators of Ingrid Hedenfalk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid Hedenfalk. Ingrid Hedenfalk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Westbom-Fremer, Sofia, et al.. (2025). Tertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: anatomical site matters. Cancer Immunology Immunotherapy. 74(2). 56–56. 2 indexed citations

Fleischer, Thomas, Mads H. Haugen, Laxmi Silwal‐Pandit, et al.. (2024). An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer. Molecular Oncology. 18(8). 2042–2059. 3 indexed citations

Westbom-Fremer, Sofia, et al.. (2020). SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery. Molecular & Cellular Oncology. 7(6). 1805094–1805094. 7 indexed citations

Menard, Julien A., Vineesh Indira Chandran, Maria C. Johansson, et al.. (2019). Extracellular lipid loading augments hypoxic paracrine signaling and promotes glioma angiogenesis and macrophage infiltration. Journal of Experimental & Clinical Cancer Research. 38(1). 241–241. 27 indexed citations

Haugen, Mads H., Ole Christian Lingjærde, Oslo Garred, et al.. (2019). Design of a protein signature predicting response to neo-adjuvant treatment with chemotherapy combined with bevacizumab in breast cancer patients. Annals of Oncology. 30. iii8–iii8.

Severson, Tesa, Yongsoo Kim, Stacey E. P. Joosten, et al.. (2018). Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. Nature Communications. 9(1). 482–482. 51 indexed citations

Lawler, Katherine, Efterpi Papouli, Cristina Naceur‐Lombardelli, et al.. (2017). Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. Breast Cancer Research. 19(1). 113–113. 4 indexed citations

Palazón, Asís, Petros A. Tyrakis, David Macías, et al.. (2017). An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell. 32(5). 669–683.e5. 408 indexed citations breakdown →

Kimbung, Siker, Ida Johansson, Anna Danielsson, et al.. (2015). Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. Clinical Cancer Research. 22(1). 146–157. 36 indexed citations

10.

Bjarnadottir, Olöf, Siker Kimbung, Ida Johansson, et al.. (2015). Global Transcriptional Changes Following Statin Treatment in Breast Cancer. Clinical Cancer Research. 21(15). 3402–3411. 45 indexed citations

11.

Johansson, Ida, Mev Dominguez–Valentin, Siker Kimbung, et al.. (2014). Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. PLoS ONE. 9(9). e107643–e107643. 13 indexed citations

12.

Johansson, Ida, Fredrika Killander, Barbro Linderholm, & Ingrid Hedenfalk. (2014). Molecular profiling of male breast cancer – Lost in translation?. The International Journal of Biochemistry & Cell Biology. 53. 526–535. 34 indexed citations

13.

Johansson, Ida, Markus Ringnér, & Ingrid Hedenfalk. (2013). The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer. PLoS ONE. 8(10). e78299–e78299. 37 indexed citations

14.

Nilsson, Cecilia, Ida Johansson, Cecilia Ahlin, et al.. (2012). Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncologica. 52(1). 102–109. 41 indexed citations

15.

Ceder, Rebecca, Giulio Preta, Katja Pokrovskaja Tamm, et al.. (2012). Requirement of Apoptotic Protease-Activating Factor-1 for Bortezomib-Induced Apoptosis but Not for Fas-Mediated Apoptosis in Human Leukemic Cells. Molecular Pharmacology. 83(1). 245–255. 9 indexed citations

16.

Kimbung, Siker, Ida Johansson, Kristina Aaltonen, et al.. (2012). Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Letters. 319(2). 232–241. 37 indexed citations

17.

Johansson, Ida, Kristina Aaltonen, Dorthe Grabau, et al.. (2011). Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. Genes Chromosomes and Cancer. 51(4). 375–383. 29 indexed citations

18.

Rennstam, Karin, Anita Ringberg, Heather E. Cunliffe, et al.. (2009). Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes and Cancer. 49(1). 78–90. 19 indexed citations

19.

Rennstam, Karin & Ingrid Hedenfalk. (2006). High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer. Breast Cancer Research. 8(4). 213–213. 14 indexed citations

20.

Kronblad, Åsa, Ingrid Hedenfalk, Elise Nilsson, Sven Påhlman, & Göran Landberg. (2005). ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERα: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene. 24(45). 6835–6841. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact